BAYER AG-REG (BAYN.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:BAYN - DE000BAY0017 - Common Stock
39.59 EUR
+0.71 (+1.83%)
Overall BAYN gets a fundamental rating of 3 out of 10. We evaluated BAYN against 53 industry peers in the Pharmaceuticals industry. BAYN may be in some trouble as it scores bad on both profitability and health. BAYN is valued quite cheap, but it does not seem to be growing.
1. Profitability
1.1 Basic Checks
In the past year BAYN was profitable.
BAYN had a positive operating cash flow in the past year.
In multiple years BAYN reported negative net income over the last 5 years.
In the past 5 years BAYN always reported a positive cash flow from operatings.
1.2 Ratios
BAYN has a worse Return On Assets (-0.19%) than 66.04% of its industry peers.
The Return On Equity of BAYN (-0.67%) is worse than 66.04% of its industry peers.
With a Return On Invested Capital value of 1.80%, BAYN is not doing good in the industry: 66.04% of the companies in the same industry are doing better.
The Average Return On Invested Capital over the past 3 years for BAYN is significantly below the industry average of 14.02%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.19% | ||
| ROE | -0.67% | ||
| ROIC | 1.8% |
ROA(3y)-0.5%
ROA(5y)-1.93%
ROE(3y)-2.08%
ROE(5y)-7.52%
ROIC(3y)5.51%
ROIC(5y)N/A
1.3 Margins
BAYN has a Operating Margin of 4.20%. This is in the lower half of the industry: BAYN underperforms 64.15% of its industry peers.
In the last couple of years the Operating Margin of BAYN has declined.
BAYN has a worse Gross Margin (56.35%) than 67.92% of its industry peers.
BAYN's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 4.2% | ||
| PM (TTM) | N/A | ||
| GM | 56.35% |
OM growth 3Y-18.1%
OM growth 5Y-4.34%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.21%
GM growth 5Y-1.81%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so BAYN is destroying value.
Compared to 1 year ago, BAYN has about the same amount of shares outstanding.
The number of shares outstanding for BAYN remains at a similar level compared to 5 years ago.
The debt/assets ratio for BAYN has been reduced compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of 0.97, we must say that BAYN is in the distress zone and has some risk of bankruptcy.
BAYN's Altman-Z score of 0.97 is on the low side compared to the rest of the industry. BAYN is outperformed by 69.81% of its industry peers.
BAYN has a debt to FCF ratio of 10.07. This is a negative value and a sign of low solvency as BAYN would need 10.07 years to pay back of all of its debts.
With a Debt to FCF ratio value of 10.07, BAYN is not doing good in the industry: 60.38% of the companies in the same industry are doing better.
BAYN has a Debt/Equity ratio of 1.11. This is a high value indicating a heavy dependency on external financing.
BAYN has a worse Debt to Equity ratio (1.11) than 66.04% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.11 | ||
| Debt/FCF | 10.07 | ||
| Altman-Z | 0.97 |
ROIC/WACC0.27
WACC6.65%
2.3 Liquidity
BAYN has a Current Ratio of 1.14. This is a normal value and indicates that BAYN is financially healthy and should not expect problems in meeting its short term obligations.
The Current ratio of BAYN (1.14) is worse than 62.26% of its industry peers.
A Quick Ratio of 0.71 indicates that BAYN may have some problems paying its short term obligations.
With a Quick ratio value of 0.71, BAYN is not doing good in the industry: 69.81% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.14 | ||
| Quick Ratio | 0.71 |
3. Growth
3.1 Past
BAYN shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -8.72%.
Measured over the past years, BAYN shows a decrease in Earnings Per Share. The EPS has been decreasing by -5.27% on average per year.
BAYN shows a decrease in Revenue. In the last year, the revenue decreased by -1.87%.
BAYN shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 1.37% yearly.
EPS 1Y (TTM)-8.72%
EPS 3Y-8.12%
EPS 5Y-5.27%
EPS Q2Q%137.5%
Revenue 1Y (TTM)-1.87%
Revenue growth 3Y1.87%
Revenue growth 5Y1.37%
Sales Q2Q%-3.09%
3.2 Future
BAYN is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 3.51% yearly.
The Revenue is expected to grow by 1.22% on average over the next years.
EPS Next Y-5.16%
EPS Next 2Y-1.81%
EPS Next 3Y1.63%
EPS Next 5Y3.51%
Revenue Next Year-1.56%
Revenue Next 2Y-0.38%
Revenue Next 3Y0.49%
Revenue Next 5Y1.22%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 7.41, which indicates a rather cheap valuation of BAYN.
Based on the Price/Earnings ratio, BAYN is valued cheaper than 98.11% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 27.19. BAYN is valued rather cheaply when compared to this.
A Price/Forward Earnings ratio of 8.13 indicates a reasonable valuation of BAYN.
Based on the Price/Forward Earnings ratio, BAYN is valued cheaply inside the industry as 96.23% of the companies are valued more expensively.
Compared to an average S&P500 Price/Forward Earnings ratio of 23.92, BAYN is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 7.41 | ||
| Fwd PE | 8.13 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of BAYN indicates a somewhat cheap valuation: BAYN is cheaper than 64.15% of the companies listed in the same industry.
Based on the Price/Free Cash Flow ratio, BAYN is valued cheaper than 90.57% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 9.88 | ||
| EV/EBITDA | 11.27 |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-1.81%
EPS Next 3Y1.63%
5. Dividend
5.1 Amount
BAYN has a yearly dividend return of 0.28%, which is pretty low.
BAYN's Dividend Yield is slightly below the industry average, which is at 1.72.
With a Dividend Yield of 0.28, BAYN pays less dividend than the S&P500 average, which is at 1.92.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.28% |
5.2 History
The dividend of BAYN decreases each year by -45.34%.
Dividend Growth(5Y)-45.34%
Div Incr Years0
Div Non Decr Years3
5.3 Sustainability
The earnings of BAYN are negative and hence is the payout ratio. BAYN will probably not be able to sustain this dividend level.
DP-65.15%
EPS Next 2Y-1.81%
EPS Next 3Y1.63%
FRA:BAYN (1/12/2026, 4:50:03 PM)
39.59
+0.71 (+1.83%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners49.57%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap38.89B
Revenue(TTM)45.87B
Net Income(TTM)-198.00M
Analysts74.29
Price Target34.35 (-13.24%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.28% |
Yearly Dividend0.13
Dividend Growth(5Y)-45.34%
DP-65.15%
Div Incr Years0
Div Non Decr Years3
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)58.52%
Min EPS beat(2)45.89%
Max EPS beat(2)71.16%
EPS beat(4)4
Avg EPS beat(4)30.58%
Min EPS beat(4)1.86%
Max EPS beat(4)71.16%
EPS beat(8)7
Avg EPS beat(8)18.15%
EPS beat(12)9
Avg EPS beat(12)7.9%
EPS beat(16)12
Avg EPS beat(16)7.93%
Revenue beat(2)0
Avg Revenue beat(2)-2.53%
Min Revenue beat(2)-2.63%
Max Revenue beat(2)-2.42%
Revenue beat(4)1
Avg Revenue beat(4)-1.06%
Min Revenue beat(4)-2.63%
Max Revenue beat(4)1.79%
Revenue beat(8)2
Avg Revenue beat(8)-1.69%
Revenue beat(12)2
Avg Revenue beat(12)-2.67%
Revenue beat(16)6
Avg Revenue beat(16)-1.42%
PT rev (1m)5.41%
PT rev (3m)18.06%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-37.41%
EPS NY rev (1m)0.49%
EPS NY rev (3m)0.86%
Revenue NQ rev (1m)-0.01%
Revenue NQ rev (3m)-2.41%
Revenue NY rev (1m)-0.05%
Revenue NY rev (3m)-0.38%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 7.41 | ||
| Fwd PE | 8.13 | ||
| P/S | 0.85 | ||
| P/FCF | 9.88 | ||
| P/OCF | 5.79 | ||
| P/B | 1.31 | ||
| P/tB | N/A | ||
| EV/EBITDA | 11.27 |
EPS(TTM)5.34
EY13.49%
EPS(NY)4.87
Fwd EY12.3%
FCF(TTM)4.01
FCFY10.12%
OCF(TTM)6.84
OCFY17.29%
SpS46.69
BVpS30.11
TBVpS-18.8
PEG (NY)N/A
PEG (5Y)N/A
Graham Number60.14
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.19% | ||
| ROE | -0.67% | ||
| ROCE | 2.56% | ||
| ROIC | 1.8% | ||
| ROICexc | 2% | ||
| ROICexgc | 6.8% | ||
| OM | 4.2% | ||
| PM (TTM) | N/A | ||
| GM | 56.35% | ||
| FCFM | 8.58% |
ROA(3y)-0.5%
ROA(5y)-1.93%
ROE(3y)-2.08%
ROE(5y)-7.52%
ROIC(3y)5.51%
ROIC(5y)N/A
ROICexc(3y)6.21%
ROICexc(5y)N/A
ROICexgc(3y)25.79%
ROICexgc(5y)N/A
ROCE(3y)7.82%
ROCE(5y)N/A
ROICexgc growth 3Y-23.46%
ROICexgc growth 5Y-1.27%
ROICexc growth 3Y-13.2%
ROICexc growth 5Y2.54%
OM growth 3Y-18.1%
OM growth 5Y-4.34%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.21%
GM growth 5Y-1.81%
F-Score5
Asset Turnover0.44
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.11 | ||
| Debt/FCF | 10.07 | ||
| Debt/EBITDA | 5.32 | ||
| Cap/Depr | 66.1% | ||
| Cap/Sales | 6.08% | ||
| Interest Coverage | 1.09 | ||
| Cash Conversion | 109.39% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.14 | ||
| Quick Ratio | 0.71 | ||
| Altman-Z | 0.97 |
F-Score5
WACC6.65%
ROIC/WACC0.27
Cap/Depr(3y)34.81%
Cap/Depr(5y)41.62%
Cap/Sales(3y)5.85%
Cap/Sales(5y)5.86%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-8.72%
EPS 3Y-8.12%
EPS 5Y-5.27%
EPS Q2Q%137.5%
EPS Next Y-5.16%
EPS Next 2Y-1.81%
EPS Next 3Y1.63%
EPS Next 5Y3.51%
Revenue 1Y (TTM)-1.87%
Revenue growth 3Y1.87%
Revenue growth 5Y1.37%
Sales Q2Q%-3.09%
Revenue Next Year-1.56%
Revenue Next 2Y-0.38%
Revenue Next 3Y0.49%
Revenue Next 5Y1.22%
EBIT growth 1Y-2.82%
EBIT growth 3Y-16.56%
EBIT growth 5Y-3.03%
EBIT Next Year65.28%
EBIT Next 3Y21.41%
EBIT Next 5Y12.99%
FCF growth 1Y873.08%
FCF growth 3Y22.16%
FCF growth 5Y-3.69%
OCF growth 1Y161.6%
OCF growth 3Y12.83%
OCF growth 5Y-2.09%
BAYER AG-REG / BAYN.DE FAQ
What is the fundamental rating for BAYN stock?
ChartMill assigns a fundamental rating of 3 / 10 to BAYN.DE.
What is the valuation status of BAYER AG-REG (BAYN.DE) stock?
ChartMill assigns a valuation rating of 7 / 10 to BAYER AG-REG (BAYN.DE). This can be considered as Undervalued.
How profitable is BAYER AG-REG (BAYN.DE) stock?
BAYER AG-REG (BAYN.DE) has a profitability rating of 2 / 10.
How financially healthy is BAYER AG-REG?
The financial health rating of BAYER AG-REG (BAYN.DE) is 1 / 10.
How sustainable is the dividend of BAYER AG-REG (BAYN.DE) stock?
The dividend rating of BAYER AG-REG (BAYN.DE) is 0 / 10 and the dividend payout ratio is -65.15%.